Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India
- PMID: 15489554
Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India
Abstract
Background & objectives: Sodium antimony gluconate (SAG) is reported to be losing its efficacy in Bihar as a first line drug for treatment of visceral leishmaniasis (VL). Concerned with the increasing incidence of antimony-resistant VL patients in Bihar, we undertook an epidemiological, clinical and pharmacological study to formulate a scientific basis for choosing a suitable first line drug for VL.
Methods: Consecutive, fresh and parasitologically confirmed patients of VL from different geographical areas of Bihar were considered for inclusion in the study. Parasites isolated from patients were tested in vitro to assess their response to sodium antimony gluconate (SAG) to 20 microg/ml, response to 20 mg/kg of SAG for 5 days in experimentally induced VL in BALB/c mice from those isolates, and response to SAG in patients treated with SAG for 28 days. Similarly response in culture (1 microg/ml) to amphotericin B (AMB) of all 282 isolates, (1 mg/kg body wt for 20 days) in patients and infected BALB/c mice (1 mg/kg body wt for 5 days) was determined. Antimony levels of plasma were determined at 2, 8 and 24 h after intramuscular injection of SAG. Patients unwilling for SAG treatment or relapsed after SAG treatment and withdrawn from SAG group because of toxicity were treated with AMB. Plasma antimony levels were estimated by atomic absorption spectrometer.
Results: Though antimony sensitive and resistant patient were distributed in all 14 districts of Bihar studied, there was a significant variation from district to district. Of the 123 patients included in the SAG treatment group, 19 were withdrawn due to development of toxicity and 2 died; 178 patients were treated with AMB. No patient in AMB group developed any toxicity or died. Only 47 (46%) of 102 patients, 106 (37.6%) of 282 infected macrophages, 90 (52.9%) of 170 experimental infections were cured with SAG. Mc Nemar's test on paired comparisons showed statistical significance difference (P<0.01) between infected macrophage and experimental infection. AMB cured all patients, infected mice and cleared parasites from all isolates.
Interpretation & conclusion: Antimony resistant strains of L. donovani were wide spread over different geographical areas in Bihar. SAG cured lesser percentage of VL cases clinically compared to AMB and should be replaced by AMB as a first line drug.
Similar articles
-
Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.Indian J Med Res. 2008 Jun;127(6):582-8. Indian J Med Res. 2008. PMID: 18765878 Clinical Trial.
-
A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis.Ann Trop Med Parasitol. 2004 Mar;98(2):129-38. doi: 10.1179/000349804225003154. Ann Trop Med Parasitol. 2004. PMID: 15035723 Clinical Trial.
-
Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.Indian J Med Res. 2008 Jul;128(1):38-44. Indian J Med Res. 2008. PMID: 18820357
-
Leishmaniasis: an update of current pharmacotherapy.Expert Opin Pharmacother. 2013 Jan;14(1):53-63. doi: 10.1517/14656566.2013.755515. Epub 2012 Dec 21. Expert Opin Pharmacother. 2013. PMID: 23256501 Review.
-
Management of visceral leishmaniasis: Indian perspective.J Postgrad Med. 2005;51 Suppl 1:S53-7. J Postgrad Med. 2005. PMID: 16519257 Review.
Cited by
-
Antimony susceptible Leishmania donovani: evidence from in vitro drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era.Microbiol Spectr. 2024 Jun 4;12(6):e0402623. doi: 10.1128/spectrum.04026-23. Epub 2024 May 7. Microbiol Spectr. 2024. PMID: 38712926 Free PMC article.
-
Short-Course Treatment With Imipramine Entrapped in Squalene Liposomes Results in Sterile Cure of Experimental Visceral Leishmaniasis Induced by Antimony Resistant Leishmania donovani With Increased Efficacy.Front Cell Infect Microbiol. 2020 Nov 10;10:595415. doi: 10.3389/fcimb.2020.595415. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 33240825 Free PMC article.
-
Conversion of asymptomatic infection to symptomatic visceral leishmaniasis: A study of possible immunological markers.PLoS Negl Trop Dis. 2020 Jun 18;14(6):e0008272. doi: 10.1371/journal.pntd.0008272. eCollection 2020 Jun. PLoS Negl Trop Dis. 2020. PMID: 32555598 Free PMC article.
-
Evaluation of MDR1 and MRPA genes expression in different types of dry cutaneous leishmaniasis.BMC Res Notes. 2019 Dec 12;12(1):803. doi: 10.1186/s13104-019-4784-0. BMC Res Notes. 2019. PMID: 31831065 Free PMC article.
-
Assessment of quality of life using WHOQOL-BREF in patients with visceral leishmaniasis.Health Qual Life Outcomes. 2019 Mar 28;17(1):53. doi: 10.1186/s12955-019-1112-2. Health Qual Life Outcomes. 2019. PMID: 30922346 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources